Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 48 min ago
Peer-reviewedCC BY-NCClinical pharmacology and therapeutics

Clinical Pharmacology in Transgender Medicine: What Gaps Remain?

  • Lauren R Cirrincione1
  1. 1Department of Pharmacy, University of Washington, Seattle, Washington, USA.
Read full textPDFDOICite

Abstract

Mechanistic information is limited about the effects of gender-affirming hormone therapy and the unique factors that influence the absorption, distribution, metabolism, and excretion properties of medications across therapeutic classes for transgender people. Opportunities exist to address knowledge gaps in transgender medicine using well-designed probe substrate studies, endogenous biomarkers of drug-metabolizing enzymes and transporters, and real-world data to identify and address factors that contribute to interindividual variability in drug disposition for transgender people across the life course.

Related

  1. Chinese herbal medicine for recurrent urinary tract infection: formulation-specific clinical evidence, experimental pharmacology, and unresolved recurrence mechanisms
    Pengtian Zhang, Xuming Zhang, Chaoyue Ji +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefDOAJ
  2. Progress in the Synthesis of Evidence in Glaucoma: What We Know and the Gaps that Remain.
    Mapa Prabhath Piyasena, Gianni Virgili, Augusto Azuara-Blanco
    Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)Peer-reviewedCC BYFull text1 citedGeneral medicineEurope PMC
  3. Digital health and artificial intelligence in paediatric respiratory medicine: what clinicians need to know and what is coming next
    Mirèse Christine Lilian Kleuskens, Amy Hai Yan Chan, David Drummond
    Breathe (Sheffield, England)Peer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. Cannabinoids in oncology: pharmacology, clinical applications, and translational perspectives
    Emma Safran, Howard Safran, Stanley Kim
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  5. Epidemiology and clinical outcomes of filler-related complications among transgender women in Mexico
    Karen Aranza Marañón-Solorio, Mariana Vélez-Pintado, América Sarahí Martínez-Frías +10
    Scientific ReportsPeer-reviewedCC BY 4.0Full textGeneral medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{cirrincione2026clinical,
  title = {{Clinical Pharmacology in Transgender Medicine: What Gaps Remain?}},
  author = {Lauren R Cirrincione},
  journal = {Clinical pharmacology and therapeutics},
  year = {2026},
  month = nov,
  doi = {10.1002/cpt.70549},
  url = {https://europepmc.org/article/MED/42971942},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Clinical Pharmacology in Transgender Medicine: What Gaps Remain?
AU  - Lauren R Cirrincione
PY  - 2026
DA  - 2026/11/02
JO  - Clinical pharmacology and therapeutics
DO  - 10.1002/cpt.70549
UR  - https://europepmc.org/article/MED/42971942
AB  - Mechanistic information is limited about the effects of gender-affirming hormone therapy and the unique factors that influence the absorption, distribution, metabolism, and excretion properties of medications across therapeutic classes for transgender people. Opportunities exist to address knowledge gaps in transgender medicine using well-designed probe substrate studies, endogenous biomarkers of drug-metabolizing enzymes and transporters, and real-world data to identify and address factors that contribute to interindividual variability in drug disposition for transgender people across the life course.
SN  - 0009-9236
SN  - 1532-6535
ER  -